Home LiteratureArticle Details
PMID: 21160526 Published · ppublish English Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, Non-P.H.S. Review

RNA interference in the clinic: challenges and future directions.

Nature reviews. Cancer ·Vol. 11 ·No. 1 ·2011-01-00 ·Pages 59-67

Pecot CV, Calin GA, Coleman RL, Lopez-Berestein G, Sood AK

Abstract

Inherent difficulties with blocking many desirable targets using conventional approaches have prompted many to consider using RNA interference (RNAi) as a therapeutic approach. Although exploitation of RNAi has immense potential as a cancer therapeutic, many physiological obstacles stand in the way of successful and efficient delivery. This Review explores current challenges to the development of synthetic RNAi-based therapies and considers new approaches to circumvent biological barriers, to avoid intolerable side effects and to achieve controlled and sustained release.

MeSH Terms
Clinical Trials as Topic Humans Neoplasms/genetics,therapy RNA Interference/physiology
Authors & Affiliations
5 authors, click to expand affiliations / ORCID
Pecot Chad V
U.T. M.D. Anderson Cancer Center, Houston, Texas 77030, USA.
Calin George A
Coleman Robert L
Lopez-Berestein Gabriel
Sood Anil K
References (99)
99 references, click to expand
  1. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia.
    N Engl J Med. 2006 Dec 7;355(23):2408-17 PMID: 17151364
  2. A combinatorial library of lipid-like materials for delivery of RNAi therapeutics.
    Nat Biotechnol. 2008 May;26(5):561-9 PMID: 18438401
  3. Dicer, Drosha, and outcomes in patients with ovarian cancer.
    N Engl J Med. 2008 Dec 18;359(25):2641-50 PMID: 19092150
  4. Single-stranded antisense siRNAs guide target RNA cleavage in RNAi.
    Cell. 2002 Sep 6;110(5):563-74 PMID: 12230974
  5. Targeted gene silencing using RGD-labeled chitosan nanoparticles.
    Clin Cancer Res. 2010 Aug 1;16(15):3910-22 PMID: 20538762
  6. Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate.
    Bioconjug Chem. 2006 Jan-Feb;17(1):241-4 PMID: 16417275
  7. RNAi and iTRAQ reagents united: targeted quantitation of siRNA-mediated protein silencing in human cells.
    Anal Bioanal Chem. 2009 Oct;395(3):773-85 PMID: 19711061
  8. Cationic lipids enhance siRNA-mediated interferon response in mice.
    Biochem Biophys Res Commun. 2005 May 13;330(3):755-9 PMID: 15809061
  9. Mathematical modeling of cancer progression and response to chemotherapy.
    Expert Rev Anticancer Ther. 2006 Oct;6(10):1361-76 PMID: 17069522
  10. Sustained small interfering RNA delivery by mesoporous silicon particles.
    Cancer Res. 2010 May 1;70(9):3687-96 PMID: 20430760
  11. Extracellular barriers to in Vivo PEI and PEGylated PEI polyplex-mediated gene delivery to the liver.
    Bioconjug Chem. 2008 Mar;19(3):693-704 PMID: 18293906
  12. Chemically modified siRNA prolonged RNA interference in renal disease.
    Biochem Biophys Res Commun. 2007 Nov 16;363(2):432-7 PMID: 17880921
  13. FERM control of FAK function: implications for cancer therapy.
    Cell Cycle. 2008 Aug;7(15):2306-14 PMID: 18677107
  14. Design maps for nanoparticles targeting the diseased microvasculature.
    Biomaterials. 2008 Jan;29(3):377-84 PMID: 17936897
  15. Enabling individualized therapy through nanotechnology.
    Pharmacol Res. 2010 Aug;62(2):57-89 PMID: 20045055
  16. Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs.
    Mol Cell. 2004 Jul 23;15(2):185-97 PMID: 15260970
  17. In vivo imaging of RNA interference.
    J Nucl Med. 2010 Feb;51(2):169-72 PMID: 20080892
  18. Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application.
    Nat Rev Drug Discov. 2010 Jan;9(1):57-67 PMID: 20043028
  19. Factors affecting the clearance and biodistribution of polymeric nanoparticles.
    Mol Pharm. 2008 Jul-Aug;5(4):505-15 PMID: 18672949
  20. Coexpression of Argonaute-2 enhances RNA interference toward perfect match binding sites.
    Proc Natl Acad Sci U S A. 2008 Jul 8;105(27):9284-9 PMID: 18591665
  21. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA.
    Nat Biotechnol. 2005 Apr;23(4):457-62 PMID: 15778705
  22. Sequence- and target-independent angiogenesis suppression by siRNA via TLR3.
    Nature. 2008 Apr 3;452(7187):591-7 PMID: 18368052
  23. Translation repression in human cells by microRNA-induced gene silencing requires RCK/p54.
    PLoS Biol. 2006 Jul;4(7):e210 PMID: 16756390
  24. siRNA and innate immunity.
    Oligonucleotides. 2009 Jun;19(2):89-102 PMID: 19441890
  25. The mathematical engines of nanomedicine.
    Small. 2008 Jan;4(1):20-5 PMID: 18165947
  26. Kinetic analysis of the RNAi enzyme complex.
    Nat Struct Mol Biol. 2004 Jul;11(7):599-606 PMID: 15170178
  27. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs.
    Nature. 2004 Nov 11;432(7014):173-8 PMID: 15538359
  28. Microvascular architecture of experimental colon tumors in the rat.
    Cancer Res. 1990 Apr 15;50(8):2411-7 PMID: 2317825
  29. Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA.
    Proc Natl Acad Sci U S A. 2007 Apr 3;104(14):5715-21 PMID: 17379663
  30. Expression profiling reveals off-target gene regulation by RNAi.
    Nat Biotechnol. 2003 Jun;21(6):635-7 PMID: 12754523
  31. Regulation of tumor angiogenesis by EZH2.
    Cancer Cell. 2010 Aug 9;18(2):185-97 PMID: 20708159
  32. RNAi therapeutics: a potential new class of pharmaceutical drugs.
    Nat Chem Biol. 2006 Dec;2(12):711-9 PMID: 17108989
  33. Transfection of small RNAs globally perturbs gene regulation by endogenous microRNAs.
    Nat Biotechnol. 2009 Jun;27(6):549-55 PMID: 19465925
  34. SIK2 is a centrosome kinase required for bipolar mitotic spindle formation that provides a potential target for therapy in ovarian cancer.
    Cancer Cell. 2010 Aug 9;18(2):109-21 PMID: 20708153
  35. Common genetic variants account for differences in gene expression among ethnic groups.
    Nat Genet. 2007 Feb;39(2):226-31 PMID: 17206142
  36. Frontiers in cancer nanomedicine: directing mass transport through biological barriers.
    Trends Biotechnol. 2010 Apr;28(4):181-8 PMID: 20079548
  37. MicroRNA biogenesis: coordinated cropping and dicing.
    Nat Rev Mol Cell Biol. 2005 May;6(5):376-85 PMID: 15852042
  38. Dendrimer toxicity: Let's meet the challenge.
    Int J Pharm. 2010 Jul 15;394(1-2):122-42 PMID: 20433913
  39. Structural variations and stabilising modifications of synthetic siRNAs in mammalian cells.
    Nucleic Acids Res. 2003 Jun 1;31(11):2705-16 PMID: 12771196
  40. Nanoparticle-aptamer conjugates for cancer cell targeting and detection.
    Methods Mol Biol. 2010;624:235-48 PMID: 20217600
  41. Telomerase RNA as a detection marker in the serum of breast cancer patients.
    Clin Cancer Res. 2000 Oct;6(10):3823-6 PMID: 11051224
  42. Unlocking the potential of the human genome with RNA interference.
    Nature. 2004 Sep 16;431(7006):371-8 PMID: 15372045
  43. Cellular pharmacology of P-ethoxy antisense oligonucleotides targeted to Bcl-2 in a follicular lymphoma cell line.
    Leuk Lymphoma. 2003 Nov;44(11):1979-85 PMID: 14738153
  44. "New"-clear functions of PDK1: beyond a master kinase in the cytosol?
    J Cell Biochem. 2005 Dec 15;96(6):1157-62 PMID: 16187290
  45. Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity.
    Adv Drug Deliv Rev. 2006 Dec 1;58(14):1523-31 PMID: 17079050
  46. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
    Lancet. 2007 Jan 6;369(9555):29-36 PMID: 17208639
  47. Lipid-based nanotherapeutics for siRNA delivery.
    J Intern Med. 2010 Jan;267(1):9-21 PMID: 20059641
  48. A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs.
    Cancer Res. 1986 Dec;46(12 Pt 1):6387-92 PMID: 2946403
  49. Structural insights into RNA interference.
    Curr Opin Struct Biol. 2010 Feb;20(1):90-7 PMID: 20053548
  50. Neutrophil extracellular traps kill bacteria.
    Science. 2004 Mar 5;303(5663):1532-5 PMID: 15001782
  51. Breaking down the barriers: siRNA delivery and endosome escape.
    J Cell Sci. 2010 Apr 15;123(Pt 8):1183-9 PMID: 20356929
  52. Survival of cancer cells is maintained by EGFR independent of its kinase activity.
    Cancer Cell. 2008 May;13(5):385-93 PMID: 18455122
  53. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs.
    RNA. 2004 Feb;10(2):185-91 PMID: 14730017
  54. Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors.
    Cancer Res. 2010 Jun 1;70(11):4550-9 PMID: 20484031
  55. Chemically modified short interfering hybrids (siHYBRIDS): nanoimmunoliposome delivery in vitro and in vivo for RNAi of HER-2.
    Nucleosides Nucleotides Nucleic Acids. 2006;25(8):889-907 PMID: 16901821
  56. Lipid-like materials for low-dose, in vivo gene silencing.
    Proc Natl Acad Sci U S A. 2010 Feb 2;107(5):1864-9 PMID: 20080679
  57. Long-circulating and target-specific nanoparticles: theory to practice.
    Pharmacol Rev. 2001 Jun;53(2):283-318 PMID: 11356986
  58. Strategies for silencing human disease using RNA interference.
    Nat Rev Genet. 2007 Mar;8(3):173-84 PMID: 17304245
  59. Toxicogenomics of cationic lipid-based vectors for gene therapy: impact of microarray technology.
    Curr Drug Deliv. 2005 Oct;2(4):429-41 PMID: 16305446
  60. Regulating the regulators: posttranslational modifications of RNA silencing factors.
    Cell. 2009 Oct 2;139(1):28-31 PMID: 19804751
  61. Beyond genomics: interpreting the 93% of the human genome that does not encode proteins.
    Curr Opin Drug Discov Devel. 2010 May;13(3):350-8 PMID: 20443168
  62. Dual targeting of EphA2 and FAK in ovarian carcinoma.
    Cancer Biol Ther. 2009 Jun;8(11):1027-34 PMID: 19395869
  63. Circulating (cell-free) nucleic acids--a promising, non-invasive tool for early detection of several human diseases.
    FEBS Lett. 2007 Mar 6;581(5):795-9 PMID: 17289032
  64. Single-nucleotide polymorphisms inside microRNA target sites influence tumor susceptibility.
    Cancer Res. 2010 Apr 1;70(7):2789-98 PMID: 20332227
  65. Oxygen radical-mediated pulmonary toxicity induced by some cationic liposomes.
    Pharm Res. 2000 May;17(5):521-5 PMID: 10888302
  66. Widespread siRNA "off-target" transcript silencing mediated by seed region sequence complementarity.
    RNA. 2006 Jul;12(7):1179-87 PMID: 16682560
  67. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans.
    Nature. 1998 Feb 19;391(6669):806-11 PMID: 9486653
  68. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles.
    Nature. 2010 Apr 15;464(7291):1067-70 PMID: 20305636
  69. Illuminating the silence: understanding the structure and function of small RNAs.
    Nat Rev Mol Cell Biol. 2007 Jan;8(1):23-36 PMID: 17183358
  70. Pancreatic cancer microenvironment.
    Int J Cancer. 2007 Aug 15;121(4):699-705 PMID: 17534898
  71. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors.
    Cancer Res. 2004 Jun 1;64(11):3731-6 PMID: 15172975
  72. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution.
    Mol Pharm. 2008 Jul-Aug;5(4):487-95 PMID: 18510338
  73. The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses.
    Nat Immunol. 2004 Jul;5(7):730-7 PMID: 15208624
  74. Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference.
    Biomaterials. 2007 Mar;28(8):1565-71 PMID: 17161865
  75. Mechanisms and optimization of in vivo delivery of lipophilic siRNAs.
    Nat Biotechnol. 2007 Oct;25(10):1149-57 PMID: 17873866
  76. Maintaining the silence: reflections on long-term RNAi.
    Drug Discov Today. 2008 Nov;13(21-22):917-31 PMID: 18620073
  77. 3-D tissue culture systems for the evaluation and optimization of nanoparticle-based drug carriers.
    Bioconjug Chem. 2008 Oct;19(10):1951-9 PMID: 18788773
  78. Insights into the kinetics of siRNA-mediated gene silencing from live-cell and live-animal bioluminescent imaging.
    Nucleic Acids Res. 2006 Jan 12;34(1):322-33 PMID: 16410612
  79. Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo.
    Proc Natl Acad Sci U S A. 2005 Aug 23;102(34):12177-82 PMID: 16091473
  80. Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects.
    Bioconjug Chem. 2010 May 19;21(5):797-802 PMID: 20397686
  81. The receptor-mediated endocytosis of nonspherical particles.
    Biophys J. 2008 May 15;94(10):3790-7 PMID: 18234813
  82. Phagocytosis independent extracellular nanoparticle clearance by human immune cells.
    Nano Lett. 2010 Jan;10(1):59-63 PMID: 19994869
  83. The dawning era of polymer therapeutics.
    Nat Rev Drug Discov. 2003 May;2(5):347-60 PMID: 12750738
  84. Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery.
    Cancer Res. 2005 Aug 1;65(15):6910-8 PMID: 16061675
  85. Position-specific chemical modification of siRNAs reduces "off-target" transcript silencing.
    RNA. 2006 Jul;12(7):1197-205 PMID: 16682562
  86. Argonaute2 is the catalytic engine of mammalian RNAi.
    Science. 2004 Sep 3;305(5689):1437-41 PMID: 15284456
  87. Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer.
    J Control Release. 2008 Jul 14;129(2):107-16 PMID: 18486981
  88. Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer.
    Hum Gene Ther. 2006 Oct;17(10):1019-26 PMID: 17007568
  89. Dose-finding based on efficacy-toxicity trade-offs.
    Biometrics. 2004 Sep;60(3):684-93 PMID: 15339291
  90. Identification of RNA sequence motifs stimulating sequence-specific TLR8-dependent immune responses.
    J Immunol. 2008 Mar 15;180(6):3729-38 PMID: 18322178
  91. Combinatorial delivery of small interfering RNAs reduces RNAi efficacy by selective incorporation into RISC.
    Nucleic Acids Res. 2007;35(15):5154-64 PMID: 17660190
  92. The effective dispersion of nanovectors within the tumor microvasculature.
    Ann Biomed Eng. 2006 Apr;34(4):633-41 PMID: 16568349
  93. Semiconductor nanocrystals as fluorescent biological labels.
    Science. 1998 Sep 25;281(5385):2013-6 PMID: 9748157
  94. Detection of tumor messenger RNA in the serum of patients with malignant melanoma.
    Clin Cancer Res. 1999 Aug;5(8):1961-5 PMID: 10473072
  95. The widespread impact of mammalian MicroRNAs on mRNA repression and evolution.
    Science. 2005 Dec 16;310(5755):1817-21 PMID: 16308420
  96. Fatality in mice due to oversaturation of cellular microRNA/short hairpin RNA pathways.
    Nature. 2006 May 25;441(7092):537-41 PMID: 16724069
  97. The dicey role of Dicer: implications for RNAi therapy.
    Cancer Res. 2010 Apr 1;70(7):2571-4 PMID: 20179193
  98. Mechanisms of gene silencing by double-stranded RNA.
    Nature. 2004 Sep 16;431(7006):343-9 PMID: 15372041
  99. Quantum dots as contrast agents for in vivo tumor imaging: progress and issues.
    Anal Bioanal Chem. 2011 Mar;399(7):2331-42 PMID: 20658228
Article Info
Journal
Nature reviews. Cancer
Abbr.
Nat Rev Cancer
ISSN
1474-1768
DOI
10.1038/nrc2966
Published
2011-01-00
Epub
2010-00-16
Pages
59-67
Language
English
Region
England
NLM ID
101124168
PMCID
PMC3199132
Subset
IM
Grants
NCI NIH HHS · P30 CA016672 · United States
NCI NIH HHS · P50 CA098258 · United States
NCI NIH HHS · CA110793 · United States
NCI NIH HHS · P50 CA083639 · United States
NCI NIH HHS · R01 CA128797 · United States
NCI NIH HHS · CA109298 · United States
NCI NIH HHS · CA128797 · United States
NCI NIH HHS · R01 CA109298 · United States
NIGMS NIH HHS · RC2GM092599 · United States
NCI NIH HHS · U54 CA151668 · United States
NCI NIH HHS · R01 CA110793 · United States
NIGMS NIH HHS · RC2 GM092599 · United States
External Links
PubMed source DOI: 10.1038/nrc2966 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2